Egalet Corporation (NASDAQ:EGLT) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

Beginning January9, 2017, Bob Radie, President and Chief
Executive Officer of Egalet Corporation (the Company), will be
using the presentation furnished as Exhibit99.1 hereto at J.P.
Morgans Annual Healthcare Conference in San Francisco,
California.

The information set forth this Item 7.01 (including Exhibit99.1)
is being furnished to Item 7.01 and shall not be deemed to be
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits

About Egalet Corporation (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Egalet Corporation (NASDAQ:EGLT) Recent Trading Information

Egalet Corporation (NASDAQ:EGLT) closed its last trading session up +1.22 at 9.12 with 438,619 shares trading hands.